rtization of fair value inventory for the Sunstone
acquisition, and $470,000 of amortization for the Sunstone acquisition. The
Company incurs significant non-cash charges for depreciation, amortization
and stock compensation expense that may not reflect the Company's operating
performance and ability to generate cash flow from operations. Management
believes that adjusted EBITDA is a worthwhile indicator of the Company's
financial performance. Adjusted EBITDA is a non-GAAP financial measure
within the meaning of the Securities and Exchange Commission (SEC)
regulations. A reconciliation of Adjusted EBITDA to net income is included
in a table at the end of this press release.
Net loss was $2.5 million, or ($0.07) per diluted share. On a pro forma
basis, assuming the Sunstone acquisition was completed on January 1, 2008,
revenues would be $26.8 million, net loss would be ($1.4) million and EPS
would be ($0.04) in the first quarter of 2008.
Balance Sheet
As of March 31, 2008, the Company had cash and cash equivalents as well
as bills receivable totaling $22.8 million. This compares to $22.8 million
as of December 31, 2007. The Company had long-term debt of approximately
$22.5 million as of March 31, 2008.
Business Update
On May 6, 2008, the clinical trial application for Enablex was
officially accepted by China's State Food & Drug Administration. The
clinical trial application acceptance is a key requirement to pursuing the
clinical trial and an integral step toward the completion of the Enablex
commercialization process in China.
Financial Outlook
The Company continues to expect to reach revenue of at least $96.0
million in the full year 2008, with a corresponding net loss of roughly
$3.0 million, or $0.07 per share, based on 39.5 million shares outstanding.
This financial guidance includes the impact of approximately $9.0 million
of non-cash expenses through the year, including but not limited to the
amortization of the
'/>"/>
SOURCE BMP Sunstone Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1.
BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief2.
BMP Sunstone Announces Participation in May Investor Conferences3.
BMP Sunstone to Report First Quarter 2008 Financial Results4.
BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association5.
Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 20086.
CEL-SCI Corporation Reports Second Quarter 2008 Financial Results7.
Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 20088.
China Yingxia International, Inc. Reports First Quarter 2008 Results9.
Digital Power Reports Financial Results for the First Quarter Ended March 31, 200810.
Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 200811.
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008